ロード中...
Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CA...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572744/ https://ncbi.nlm.nih.gov/pubmed/31354288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S177844 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|